APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

DPP-4 Inhibitor Hypoglycemic Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global DPP-4 Inhibitor Hypoglycemic Drugs Industry Growth and Trends Forecast to 2032

Report ID 173985960122 December 2025118 pages

Choose your research edition.

Industry ResearchDPP-4 Inhibitor Hypoglycemic Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal DPP-4 Inhibitor Hypoglycemic Drugs Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal DPP-4 Inhibitor Hypoglycemic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DPP-4 Inhibitor Hypoglycemic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal DPP-4 Inhibitor Hypoglycemic Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global DPP-4 Inhibitor Hypoglycemic Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for DPP-4 Inhibitor Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for DPP-4 Inhibitor Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DPP-4 Inhibitor Hypoglycemic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of DPP-4 Inhibitor Hypoglycemic Drugs include Chia Tai-Tianqing Pharmaceutical, YOKO Pharmaceutical, Reyoung Pharmaceutical, QILU Pharmaceutical, Novartis, Merck, Langnuo Pharmaceutical, Kelun Pharmaceutical and Huahai Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global DPP-4 Inhibitor Hypoglycemic Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The DPP-4 Inhibitor Hypoglycemic Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global DPP-4 Inhibitor Hypoglycemic Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to DPP-4 Inhibitor Hypoglycemic Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global DPP-4 Inhibitor Hypoglycemic Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

DPP-4 Inhibitor Hypoglycemic Drugs Market by Company

Chia Tai-Tianqing Pharmaceutical

YOKO Pharmaceutical

Reyoung Pharmaceutical

QILU Pharmaceutical

Novartis

Merck

Langnuo Pharmaceutical

Kelun Pharmaceutical

Huahai Pharmaceutical

Gan & Lee Pharmaceuticals

Disainuo Pharmaceutical

AstraZeneca Pharmaceuticals

Takeda Pharmaceutical

MSD Pharma

Boehringer Ingelheim International

DPP-4 Inhibitor Hypoglycemic Drugs Segment by Type

Alogliptin

Linagliptin

Saxagliptin

Vildagliptin

Sitagliptin

Others

DPP-4 Inhibitor Hypoglycemic Drugs Segment by Application

Hospital

Clinic

DPP-4 Inhibitor Hypoglycemic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DPP-4 Inhibitor Hypoglycemic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DPP-4 Inhibitor Hypoglycemic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DPP-4 Inhibitor Hypoglycemic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of DPP-4 Inhibitor Hypoglycemic Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of DPP-4 Inhibitor Hypoglycemic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Alogliptin Table 2. Major Company of Linagliptin Table 3. Major Company of Saxagliptin Table 4. Major Company of Vildagliptin Table 5. Major Company of Sitagliptin Table 6. Major Company of Others Table 7. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (k units) Table 9. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type (2021-2026) Table 10. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (US$ Million) Table 11. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type (2021-2026) Table 12. Global DPP-4 Inhibitor Hypoglycemic Drugs Price by Type (2021-2026) & (US$/unit) Table 13. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2027-2032) & (k units) Table 14. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type (2027-2032) Table 15. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2027-2032) & (US$ Million) Table 16. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type (2027-2032) Table 17. Global DPP-4 Inhibitor Hypoglycemic Drugs Price by Type (2027-2032) & (US$/unit) Table 18. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (k units) Table 19. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (k units) Table 21. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (k units) Table 23. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (k units) Table 25. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (k units) Table 27. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. DPP-4 Inhibitor Hypoglycemic Drugs Industry Trends Table 29. DPP-4 Inhibitor Hypoglycemic Drugs Industry Drivers Table 30. DPP-4 Inhibitor Hypoglycemic Drugs Industry Opportunities and Challenges Table 31. DPP-4 Inhibitor Hypoglycemic Drugs Industry Restraints Table 32. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global DPP-4 Inhibitor Hypoglycemic Drugs Revenue Market Share by Company (2021-2026) Table 34. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Company (2021-2026) & (k units) Table 35. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Share by Company (2021-2026) Table 36. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Price by Company (2021-2026) & (US$/unit) Table 37. Global DPP-4 Inhibitor Hypoglycemic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global DPP-4 Inhibitor Hypoglycemic Drugs Major Company Production Sites and Headquarters Table 39. Global DPP-4 Inhibitor Hypoglycemic Drugs Company, Product Type & Application Table 40. Global DPP-4 Inhibitor Hypoglycemic Drugs Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global DPP-4 Inhibitor Hypoglycemic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region (2021-2026) & (k units) Table 45. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Region (2021-2026) Table 46. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region (2021-2026) & (US$ Million) Table 47. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Region (2021-2026) Table 48. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 49. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region (2027-2032) & (k units) Table 50. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Region (2027-2032) Table 51. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Region (2027-2032) & (US$ Million) Table 52. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Region (2027-2032) Table 53. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 54. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (k units) Table 56. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application (2021-2026) Table 57. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (US$ Million) Table 58. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application (2021-2026) Table 59. Global DPP-4 Inhibitor Hypoglycemic Drugs Price by Application (2021-2026) & (US$/unit) Table 60. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2027-2032) & (k units) Table 61. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application (2027-2032) Table 62. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2027-2032) & (US$ Million) Table 63. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application (2027-2032) Table 64. Global DPP-4 Inhibitor Hypoglycemic Drugs Price by Application (2027-2032) & (US$/unit) Table 65. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (k units) Table 66. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (k units) Table 68. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (k units) Table 70. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (k units) Table 72. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (k units) Table 74. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Chia Tai-Tianqing Pharmaceutical Company Information Table 76. Chia Tai-Tianqing Pharmaceutical Business Overview Table 77. Chia Tai-Tianqing Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Chia Tai-Tianqing Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 79. Chia Tai-Tianqing Pharmaceutical Recent Development Table 80. YOKO Pharmaceutical Company Information Table 81. YOKO Pharmaceutical Business Overview Table 82. YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 84. YOKO Pharmaceutical Recent Development Table 85. Reyoung Pharmaceutical Company Information Table 86. Reyoung Pharmaceutical Business Overview Table 87. Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 89. Reyoung Pharmaceutical Recent Development Table 90. QILU Pharmaceutical Company Information Table 91. QILU Pharmaceutical Business Overview Table 92. QILU Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. QILU Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 94. QILU Pharmaceutical Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Novartis DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 99. Novartis Recent Development Table 100. Merck Company Information Table 101. Merck Business Overview Table 102. Merck DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Merck DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 104. Merck Recent Development Table 105. Langnuo Pharmaceutical Company Information Table 106. Langnuo Pharmaceutical Business Overview Table 107. Langnuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Langnuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 109. Langnuo Pharmaceutical Recent Development Table 110. Kelun Pharmaceutical Company Information Table 111. Kelun Pharmaceutical Business Overview Table 112. Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 114. Kelun Pharmaceutical Recent Development Table 115. Huahai Pharmaceutical Company Information Table 116. Huahai Pharmaceutical Business Overview Table 117. Huahai Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Huahai Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 119. Huahai Pharmaceutical Recent Development Table 120. Gan & Lee Pharmaceuticals Company Information Table 121. Gan & Lee Pharmaceuticals Business Overview Table 122. Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 124. Gan & Lee Pharmaceuticals Recent Development Table 125. Disainuo Pharmaceutical Company Information Table 126. Disainuo Pharmaceutical Business Overview Table 127. Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 129. Disainuo Pharmaceutical Recent Development Table 130. AstraZeneca Pharmaceuticals Company Information Table 131. AstraZeneca Pharmaceuticals Business Overview Table 132. AstraZeneca Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. AstraZeneca Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 134. AstraZeneca Pharmaceuticals Recent Development Table 135. Takeda Pharmaceutical Company Information Table 136. Takeda Pharmaceutical Business Overview Table 137. Takeda Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 138. Takeda Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 139. Takeda Pharmaceutical Recent Development Table 140. MSD Pharma Company Information Table 141. MSD Pharma Business Overview Table 142. MSD Pharma DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 143. MSD Pharma DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 144. MSD Pharma Recent Development Table 145. Boehringer Ingelheim International Company Information Table 146. Boehringer Ingelheim International Business Overview Table 147. Boehringer Ingelheim International DPP-4 Inhibitor Hypoglycemic Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 148. Boehringer Ingelheim International DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio Table 149. Boehringer Ingelheim International Recent Development Table 150. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 151. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026) & (k units) Table 152. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share by Country (2021-2026) Table 153. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 154. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share Forecast by Country (2027-2032) Table 155. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 156. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 157. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country (2021-2026) Table 158. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 159. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Share Forecast by Country (2027-2032) Table 160. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 161. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026) & (k units) Table 162. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share by Country (2021-2026) Table 163. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 164. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share Forecast by Country (2027-2032) Table 165. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 166. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 167. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country (2021-2026) Table 168. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 169. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Share Forecast by Country (2027-2032) Table 170. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 171. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026) & (k units) Table 172. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share by Country (2021-2026) Table 173. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 174. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share Forecast by Country (2027-2032) Table 175. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 176. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 177. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country (2021-2026) Table 178. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 179. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Share Forecast by Country (2027-2032) Table 180. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 181. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026) & (k units) Table 182. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share by Country (2021-2026) Table 183. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 184. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share Forecast by Country (2027-2032) Table 185. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 186. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 187. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country (2021-2026) Table 188. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 189. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Share Forecast by Country (2027-2032) Table 190. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 191. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026) & (k units) Table 192. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share by Country (2021-2026) Table 193. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032) & (k units) Table 194. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share Forecast by Country (2027-2032) Table 195. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 196. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026) & (US$ Million) Table 197. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country (2021-2026) Table 198. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 199. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Share Forecast by Country (2027-2032) Table 200. Key Raw Materials Table 201. Raw Materials Key Suppliers Table 202. DPP-4 Inhibitor Hypoglycemic Drugs Distributors List Table 203. DPP-4 Inhibitor Hypoglycemic Drugs Customers List Table 204. Research Programs/Design for This Report Table 205. Authors List of This Report Table 206. Secondary Sources Table 207. Primary Sources List of Figures Figure 1. DPP-4 Inhibitor Hypoglycemic Drugs Image Figure 2. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global DPP-4 Inhibitor Hypoglycemic Drugs Sales (2021-2032) & (k units) Figure 5. Alogliptin Image Figure 6. Global Alogliptin Sales YoY Growth (2021-2032) & (k units) Figure 7. Linagliptin Image Figure 8. Global Linagliptin Sales YoY Growth (2021-2032) & (k units) Figure 9. Saxagliptin Image Figure 10. Global Saxagliptin Sales YoY Growth (2021-2032) & (k units) Figure 11. Vildagliptin Image Figure 12. Global Vildagliptin Sales YoY Growth (2021-2032) & (k units) Figure 13. Sitagliptin Image Figure 14. Global Sitagliptin Sales YoY Growth (2021-2032) & (k units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 17. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Type 2025 VS 2032 Figure 19. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type in 2025 Figure 20. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type in 2025 Figure 21. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type in 2025 Figure 25. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 DPP-4 Inhibitor Hypoglycemic Drugs Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Hospital Image Figure 32. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 33. Clinic Image Figure 34. Global Clinic Sales YoY Growth (2021-2032) & (k units) Figure 35. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Application 2025 VS 2032 Figure 37. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application in 2025 Figure 38. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application in 2025 Figure 39. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application in 2025 Figure 43. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Market Share in Value by Application in 2025 Figure 47. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. DPP-4 Inhibitor Hypoglycemic Drugs Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. DPP-4 Inhibitor Hypoglycemic Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Saxagliptin
  • Vildagliptin
  • Sitagliptin
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • Chia Tai-Tianqing Pharmaceutical
  • YOKO Pharmaceutical
  • Reyoung Pharmaceutical
  • QILU Pharmaceutical
  • Novartis
  • Merck
  • Langnuo Pharmaceutical
  • Kelun Pharmaceutical
  • Huahai Pharmaceutical
  • Gan & Lee Pharmaceuticals
  • Disainuo Pharmaceutical
  • AstraZeneca Pharmaceuticals
  • Takeda Pharmaceutical
  • MSD Pharma
  • Boehringer Ingelheim International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 DPP-4 Inhibitor Hypoglycemic Drugs Market by Type
  6. 1.3.1 Alogliptin
  7. 1.3.2 Linagliptin
  8. 1.3.3 Saxagliptin
  9. 1.3.4 Vildagliptin
  10. 1.3.5 Sitagliptin
  11. 1.3.6 Others
  12. 1.4 Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Type
  13. 1.4.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 DPP-4 Inhibitor Hypoglycemic Drugs Industry Trends
  2. 2.2 DPP-4 Inhibitor Hypoglycemic Drugs Industry Drivers
  3. 2.3 DPP-4 Inhibitor Hypoglycemic Drugs Industry Opportunities and Challenges
  4. 2.4 DPP-4 Inhibitor Hypoglycemic Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by DPP-4 Inhibitor Hypoglycemic Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by DPP-4 Inhibitor Hypoglycemic Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by DPP-4 Inhibitor Hypoglycemic Drugs Price (2021-2026)
  4. 3.4 Global DPP-4 Inhibitor Hypoglycemic Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global DPP-4 Inhibitor Hypoglycemic Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global DPP-4 Inhibitor Hypoglycemic Drugs Company, Product Type & Application
  7. 3.7 Global DPP-4 Inhibitor Hypoglycemic Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 DPP-4 Inhibitor Hypoglycemic Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 DPP-4 Inhibitor Hypoglycemic Drugs Tier 1, Tier 2, and Tier 3
4 DPP-4 Inhibitor Hypoglycemic Drugs Regional Status and Outlook
  1. 4.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Historic Market Size by Region
  3. 4.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Forecasted Market Size by Region
  7. 4.3.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 DPP-4 Inhibitor Hypoglycemic Drugs by Application
  1. 5.1 DPP-4 Inhibitor Hypoglycemic Drugs Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Application
  5. 5.2.1 Global DPP-4 Inhibitor Hypoglycemic Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global DPP-4 Inhibitor Hypoglycemic Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global DPP-4 Inhibitor Hypoglycemic Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chia Tai-Tianqing Pharmaceutical
  2. 6.1.1 Chia Tai-Tianqing Pharmaceutical Company Information
  3. 6.1.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 6.1.3 Chia Tai-Tianqing Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chia Tai-Tianqing Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  6. 6.1.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 6.2 YOKO Pharmaceutical
  8. 6.2.1 YOKO Pharmaceutical Company Information
  9. 6.2.2 YOKO Pharmaceutical Business Overview
  10. 6.2.3 YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 YOKO Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  12. 6.2.5 YOKO Pharmaceutical Recent Developments
  13. 6.3 Reyoung Pharmaceutical
  14. 6.3.1 Reyoung Pharmaceutical Company Information
  15. 6.3.2 Reyoung Pharmaceutical Business Overview
  16. 6.3.3 Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Reyoung Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  18. 6.3.5 Reyoung Pharmaceutical Recent Developments
  19. 6.4 QILU Pharmaceutical
  20. 6.4.1 QILU Pharmaceutical Company Information
  21. 6.4.2 QILU Pharmaceutical Business Overview
  22. 6.4.3 QILU Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 QILU Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  24. 6.4.5 QILU Pharmaceutical Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Merck
  32. 6.6.1 Merck Company Information
  33. 6.6.2 Merck Business Overview
  34. 6.6.3 Merck DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Merck DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  36. 6.6.5 Merck Recent Developments
  37. 6.7 Langnuo Pharmaceutical
  38. 6.7.1 Langnuo Pharmaceutical Company Information
  39. 6.7.2 Langnuo Pharmaceutical Business Overview
  40. 6.7.3 Langnuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Langnuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  42. 6.7.5 Langnuo Pharmaceutical Recent Developments
  43. 6.8 Kelun Pharmaceutical
  44. 6.8.1 Kelun Pharmaceutical Company Information
  45. 6.8.2 Kelun Pharmaceutical Business Overview
  46. 6.8.3 Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Kelun Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  48. 6.8.5 Kelun Pharmaceutical Recent Developments
  49. 6.9 Huahai Pharmaceutical
  50. 6.9.1 Huahai Pharmaceutical Company Information
  51. 6.9.2 Huahai Pharmaceutical Business Overview
  52. 6.9.3 Huahai Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Huahai Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  54. 6.9.5 Huahai Pharmaceutical Recent Developments
  55. 6.10 Gan & Lee Pharmaceuticals
  56. 6.10.1 Gan & Lee Pharmaceuticals Company Information
  57. 6.10.2 Gan & Lee Pharmaceuticals Business Overview
  58. 6.10.3 Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Gan & Lee Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  60. 6.10.5 Gan & Lee Pharmaceuticals Recent Developments
  61. 6.11 Disainuo Pharmaceutical
  62. 6.11.1 Disainuo Pharmaceutical Company Information
  63. 6.11.2 Disainuo Pharmaceutical Business Overview
  64. 6.11.3 Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Disainuo Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  66. 6.11.5 Disainuo Pharmaceutical Recent Developments
  67. 6.12 AstraZeneca Pharmaceuticals
  68. 6.12.1 AstraZeneca Pharmaceuticals Company Information
  69. 6.12.2 AstraZeneca Pharmaceuticals Business Overview
  70. 6.12.3 AstraZeneca Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 AstraZeneca Pharmaceuticals DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  72. 6.12.5 AstraZeneca Pharmaceuticals Recent Developments
  73. 6.13 Takeda Pharmaceutical
  74. 6.13.1 Takeda Pharmaceutical Company Information
  75. 6.13.2 Takeda Pharmaceutical Business Overview
  76. 6.13.3 Takeda Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Takeda Pharmaceutical DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  78. 6.13.5 Takeda Pharmaceutical Recent Developments
  79. 6.14 MSD Pharma
  80. 6.14.1 MSD Pharma Company Information
  81. 6.14.2 MSD Pharma Business Overview
  82. 6.14.3 MSD Pharma DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 MSD Pharma DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  84. 6.14.5 MSD Pharma Recent Developments
  85. 6.15 Boehringer Ingelheim International
  86. 6.15.1 Boehringer Ingelheim International Company Information
  87. 6.15.2 Boehringer Ingelheim International Business Overview
  88. 6.15.3 Boehringer Ingelheim International DPP-4 Inhibitor Hypoglycemic Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Boehringer Ingelheim International DPP-4 Inhibitor Hypoglycemic Drugs Product Portfolio
  90. 6.15.5 Boehringer Ingelheim International Recent Developments
7 North America by Country
  1. 7.1 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country
  2. 7.1.1 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country
  6. 7.2.1 North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country
  2. 8.1.1 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country
  6. 8.2.1 Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country
  2. 9.1.1 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country
  2. 10.1.1 South America DPP-4 Inhibitor Hypoglycemic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country
  6. 10.2.1 South America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country
  2. 11.1.1 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa DPP-4 Inhibitor Hypoglycemic Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 DPP-4 Inhibitor Hypoglycemic Drugs Value Chain Analysis
  2. 12.1.1 DPP-4 Inhibitor Hypoglycemic Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 DPP-4 Inhibitor Hypoglycemic Drugs Production Mode & Process
  7. 12.2 DPP-4 Inhibitor Hypoglycemic Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 DPP-4 Inhibitor Hypoglycemic Drugs Distributors
  10. 12.2.3 DPP-4 Inhibitor Hypoglycemic Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst